THE FDA HAS ISSUED THIS WARNING AND YOU CAN READ THE ENTIRE ANNOUNCEMENT BY VISITING THEIR WEBSITE: FDA.GOV
ISSUE: FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on their in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with Uloric.
Patients should tell your health care professional if you have a history of heart problems or stroke and discuss the benefits and risks of using Uloric to treat your gout. Do not stop taking Uloric without first talking to your health care professional, as doing so can worsen your gout.
Seek emergency medical attention right away if you experience the following symptoms while taking Uloric:
Chest pain, Shortness of breath, Rapid or irregular heartbeat, Numbness or weakness on one side of your body, Dizziness, Trouble talking, and sudden severe headache.
Health care professionals should reserve Uloric for use only in patients who have failed or do not tolerate allopurinol. Counsel patients about the cardiovascular risk with Uloric and advise them to seek medical attention immediately if they experience the symptoms listed above.
Learn more about what gout is: https://www.niams.nih.gov/health-topics/gout